Amikacin treatment for multidrug resistant tuberculosis: How much monitoring is required?

European Respiratory Journal

Volumn 42, Issue 4, 2013, Pages 1148-1150

  Melchionda, Veronica ^a   Wyatt, Harry ^a   Capocci, Santino ^a,b   Medina, Raul Garcia ^c   Solamalai, Angelita ^c   Katiri, Sotira ^c   Hopkins, Susan ^c   Cropley, Ian ^c   Lipman, Marc ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN;

ADULT; AUDITORY SYSTEM EXAMINATION; CLINICAL ARTICLE; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEARING IMPAIRMENT; HUMAN; LETTER; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; OTOTOXICITY; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; RETROSPECTIVE STUDY; TINNITUS; WORLD HEALTH ORGANIZATION;

ADULT; AMIKACIN; ANTITUBERCULAR AGENTS; AUDIOLOGY; DRUG MONITORING; FEMALE; HEARING LOSS; HUMANS; KIDNEY; MALE; RETROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84886488162     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00184312     Document Type: Letter

References (11)

1. World Health Organization. Treatment of Tuberculosis Guidelines. 4th edn. Geneva, World Health Organization, 2010.
2. Sturdy A, Goodman A, José RJ, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 2011; 66: 1815-1820.
3. Constantinescu RM, Georgescu M, Pascu A, et al. Otoacoustic emissions analysers for monitoring aminoglycosides ototoxicity. Rom J Intern Med 2009; 47: 273-278.
4. Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord 2007; 7: 5.
5. American Academy of Audiology. American Academy of Audiology Position Statement and Clinical Practice Guidelines - Ototoxicity Monitoring. Reston, American Academy of Audiology, 2009. Available from: www.audiology.org/ resources/documentlibrary/Pages/OtotoxicityMonitoring.aspx
6. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002; 6: 622-627.
7. Seddon JA, Godfrey-Faussett P, Jacobs K, et al. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J 2012; 40: 1277-1286.
8. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004; 38: 1538-1544.
9. Al-Malky G, Suri R, Dawson SJ, et al. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: a study using extended high-frequency audiometry and distortion product otoacoustic emissions. Int J Audiol 2011; 50: 112-122.
10. Feldman L, Efrati S, Eviatar E, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by Nacetylcysteine. Kidney Int 2007; 72: 359-363.
11. Harris T, Bardien S, Schaaf HS, et al. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S Afr Med J 2012; 102: 363-366.